Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Specific Phenotype Narrows Risk of Preeclampsia

By LabMedica International staff writers
Posted on 10 Sep 2019
Preeclampsia can lead to a baby being born early and can put the mother at risk of a seizure or stroke during delivery. It can also lead to damage in the kidneys, liver, lungs, heart or eyes and can increase a patient's risk for cardiovascular disease in the future.

The general female population has a 5% chance of developing preeclampsia during pregnancy, but that chance increases to 20% for diabetic women. Haptoglobin (Hp), a protein with functional genetic polymorphisms, has antioxidant, anti-inflammatory and angiogenic effects. Among people with diabetes, Hp 2-2 phenotype is associated with cardio-renal disease.

Endocrinologists at the Medical University of South Carolina (Charleston, SC, USA) and their colleagues investigated whether Hp phenotype is associated with preeclampsia (PE) in type 1 diabetes (T1DM), and/or modulates lipoprotein-associated risks. Included in the multicenter prospective study were 47pregnant women with T1DM (normal albuminuria, normotensive at enrolment, studied at three visits (V1-V3), all preceding PE onset: 12.3±1.9, 21.8±1.5, and 31.5±1.6 weeks gestation (mean ± SD). The main outcome measures were Hp phenotype and lipoprotein profiles in 23 women with versus 24 without subsequent PE.

The scientists reported that Hp phenotype did not predict PE, but lipoprotein associations with subsequent PE were confined to Hp 2-2 women, in whom the following associations with PE were observed: increased LDL-cholesterol, LDL particle concentration, Apolipoprotein B (APOB), triacylglycerol/high density lipoprotein cholesterol ratio, and APOB:APOA1 ratio; decreased HDL-cholesterol, APOA1, large HDL particle concentration, and peripheral lipoprotein lipolysis. In women with one or two Hp-1 alleles, no such associations were observed.

Clare B. Kelly, PhD, an Endocrinologist and first author of the study, said, “By studying these patients, we have identified different markers that could help predict the complication before its onset. Currently, we're taking the more reactive approach when it comes to preeclampsia. But if we know a patient is diabetic and has the 2-2 phenotype, we can monitor her more closely throughout her pregnancy and treat it proactively.” The study was originally published online on June 20, 2019, in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
Medical University of South Carolina


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.